BOTB (BOTULINUM TOXIN TYPE-B), EVALUATION OF SAFETY AND TOLERABILITY IN BOTULINUM TOXIN TYPE A-RESISTANT CERVICAL DYSTONIA PATIENTS (PRELIMINARY-STUDY)
Dd. Truong et al., BOTB (BOTULINUM TOXIN TYPE-B), EVALUATION OF SAFETY AND TOLERABILITY IN BOTULINUM TOXIN TYPE A-RESISTANT CERVICAL DYSTONIA PATIENTS (PRELIMINARY-STUDY), Movement disorders, 12(5), 1997, pp. 772-775
Botulinum toxin (BTX) injection is considered the treatment of choice
for patients with cervical dystonia (torticollis). We conducted a pilo
t, open-label, dose-escalation study with BTX type B in 12 patients wh
o no longer responded clinically to injections with BTX type A. At the
doses tested, BTX type B was safe and well tolerated without evidence
of dose-limiting toxicity in this patient population. Mild-to-moderat
e adverse events generally resolved quickly and included asthenia, pai
n, nausea, dysphagia, hypertonia, and tremor. No serious adverse event
s or antibodies to type-B treatment were reported, Low-dosing-session
(100-899 units) and high-dosing-session (900-1,500 units) groups were
defined based on units administered per dosing session. Toronto West e
rn Spasmodic Torticollis Rating Scale-Severity Scale (TWSTRS-Severity)
, Patient Analogue Pain Scale, and Physician and Patient Global Assess
ment Scales were measured during this study. The TWSTRS-Severity mean
maximum percent improvement from baseline demonstrated a 9.9% versus 2
8.8% difference between the low-dose and high-dose groups, respectivel
y. Effectiveness was noted for the high-dose group on the Patient Anal
ogue Pain Scale but not on the Global Assessment Scales.